{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '5. Subjects must be medically appropriate for on-demand treatment as the sole medicinal', 'management for their HAE during the study; that is, subjects must be medically', 'appropriate to be managed without prophylactic treatments for HAE.', '6. The subject must have at least 2 angioedema events as assessed by an independent expert', 'that meet all requirements below during the run-in period of 56 days beginning at the', 'screening visit:', 'The angioedema events are unique, which is defined as an angioedema event that', 'does not begin within 48 hours of the end of an angioedema event.', 'The angioedema events must have either been treated, required medical attention, or', 'be documented to cause functional impairment based on subject entry in the e-diary.', 'Functional impairment is defined as the subject being unable to perform daily', 'activities without restriction (ie, subject records that he or she is at least slightly', 'restricted in his or her daily activities during the angioedema event).', 'The angioedema events must include symptoms of swelling. The expert will consider', 'that symptoms of swelling, in addition to visible swelling, may also include', 'symptoms in the oropharyngeal or abdominal regions that are indicative of internal', 'swelling.', 'The angioedema events are confirmed by an independent expert to be angioedema', 'events.', 'Under no circumstances should the run-in angioedema event requirement for eligibility', 'be disclosed to study subjects.', '7. Female subjects must meet at least 1 of the following requirements:', 'a. Be a woman of childbearing potential (defined as a nonmenopausal adult or', 'adolescent female who has not had a hysterectomy, bilateral oophorectomy, or', 'documented ovarian failure) who agrees to use at least 1 acceptable effective', 'contraceptive method during the study and for a duration of 30 days after last dose of', 'study drug. One or more of the following methods are acceptable:', '- Surgical sterilization (ie, bilateral tubal occlusion or vasectomy of male partner)', '-', 'Placement of an intrauterine device (IUD) or intrauterine system (IUS; implanted', 'any time prior to or during screening)', '- Combined (estrogen and progesterone containing) oral hormonal contraception', 'associated with inhibition of ovulation. It must be noted that estrogen-containing', 'hormonal contraception cannot be initiated within 56 days of the screening visit.', 'Also, they cannot be initiated until the end of the study.', '- Male condom with or without spermicide', '-', 'Use of male condom with or without spermicide, together with diaphragm', 'Female subjects who report being postmenopausal for <2 years and have a', 'follicle-stimulating hormone (FSH) 40 mIU/mL must agree to use at least an', '43']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'acceptable effective contraceptive method (as proposed above) during study and', 'for 30 days after the last dose of study drug.', 'b. Be a woman of nonchildbearing potential (defined as postmenopausal for > 2 years or', 'having an FSH > 40 mIU/mL if postmenopausal 2 years or have had a', 'hysterectomy, bilateral oophorectomy, or documented ovarian failure).', 'c. Be a woman who, as a lifestyle choice, chooses to not engage in heterosexual', 'intercourse or is a woman who exclusively has female sexual partners.', '8. In the opinion of the investigator, the subject is expected to adequately comply with all', 'required study procedures for the duration of the study. The subject must demonstrate', 'adequate compliance with all study procedures required from the screening visit through', 'randomization, including diary recording of angioedema events beginning at the', 'screening visit.', '8.2.2.', 'Exclusion Criteria', 'Subjects must meet none of the numbered exclusion criteria below to be eligible for participation', 'in this study. Medications prohibited for use during the study are addressed in Section 9.7.1.', '1. Any clinically significant medical or psychiatric condition or medical history that, in the', \"opinion of the investigator or sponsor, would interfere with the subject's ability to\", 'participate in the study or increases the risk to the subject by participating in the study.', '2. Dementia, altered mental status, or any psychiatric condition, or stay in an institution', 'further to an official or court order that would prohibit the understanding or rendering of', 'informed consent or participation in the study.', '3. Anticipated use of short-term prophylaxis of angioedema events for a pre-planned', 'procedure during the screening or study periods.', '4. Concurrent diagnosis of any other type of recurrent angioedema.', '5. Clinically significant abnormal ECG at the screening visit. This includes, but is not', 'limited to, a QTcF > 470 msec for women, a QTcF > 450 msec for men, or ventricular', 'and/or atrial premature contractions that are more frequent than occasional, and/or as', 'couplets or higher in grouping.', '6. Any clinically significant history of angina, myocardial infarction, syncope, cardiac', 'arrhythmias, left ventricular hypertrophy, cardiomyopathy, or any other clinically', 'significant cardiovascular abnormality such as poorly controlled hypertension.', '7.', 'Known family history of sudden cardiac death. Family history of sudden death from HAE', 'is not exclusionary.', '8. History of or current implanted defibrillator or pacemaker.', '9. Any abnormal laboratory or urinalysis parameter at screening that, in the opinion of the', 'investigator, is clinically significant and relevant for this study. A calculated creatinine', 'clearance (CLCR) of < 30 mL/min or AST or ALT value > 3 X the upper limit of the', 'normal (ULN) reference range value obtained during screening is exclusionary.', '10. Prior enrollment in a BCX7353 study.', '44']\n\n###\n\n", "completion": "END"}